Filter articles using the following links

GenSight Biologics integrates the Enternext® PEA-PME 150 index

5th Annual Targeting Ocular Diseases, Boston (MA)

GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes

EUNOS, Budapest, Hungary

Ophthalmology Innovation Summit @ ASRS, Boston (MA)

GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics Reports Interim Financial Results for the First Half of 2017

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

GenSight Biologics launches a capital increase of approximately €20 million